文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

数学模型强调早期儿童免疫对高CMV血清阳性率国家预防先天性CMV感染的关键作用

Mathematical modelling highlights the crucial role of early childhood immunization in preventing congenital CMV in countries with high CMV seroprevalence.
PubMed 文献 · Vaccine · 2026-06-10

该研究基于代理随机模型,以巴西为高CMV血清阳性率(达90%)案例,评估不同接种策略对降低先天性CMV感染率的效果。结果显示,为12岁女孩和育龄女性接种即使提供终身完全保护也效果有限,而婴儿接种即使仅诱导相当于自然免疫的保护,也能长期大幅减少病例;若三分之二婴儿接种, modestly effective疫苗可将病例减少高达76%。结论支持婴儿期是预防cCMVi的最佳接种年龄。

要点

  • 高CMV血清阳性率国家中,婴儿接种比12岁女孩或育龄女性接种更有效预防cCMVi。
  • 即使疫苗仅诱导自然免疫水平保护,婴儿接种仍可长期大幅减少cCMVi病例。
  • 巴西模型中,三分之二婴儿接种 modestly effective疫苗可减少cCMVi病例高达76%。

核心结论

  • 婴儿期可能是所有人群中预防cCMVi的最佳CMV疫苗接种年龄,无论CMV血清阳性率高低。
  • 在高血清阳性率国家,婴儿接种可大幅减少cCMVi病例,而12岁女孩和育龄女性接种效果有限。

研究设计与样本

  • 调整现有代理随机模型(agent-based stochastic model),以巴西为高血清阳性率(达90%)测试案例,评估CMV疫苗效果。

主要发现

  • 为12岁女孩和育龄女性接种,即使疫苗提供终身完全保护,对降低巴西cCMVi率能力有限。
  • 婴儿接种即使仅诱导相当于自然免疫对抗CMV再感染和再激活的保护,也预测可长期大幅减少巴西cCMVi病例数。
  • 若三分之二巴西婴儿接种, modestly effective疫苗可减少cCMVi病例高达76%。

临床怎么用

  • 在高CMV血清阳性率国家,预防cCMVi应优先考虑婴儿期CMV疫苗接种策略。
  • 婴儿接种即使疫苗效果 modest,也可能通过群体免疫长期显著降低cCMVi负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Congenital cytomegalovirus infection (cCMVi) is a major global health problem and a leading cause of childhood hearing, visual, and intellectual disability. Development of an effective vaccine against CMV is a high priority, and there is optimism that one will be achieved soon. Previous mathematical modelling to predict the impact of CMV vaccination in low CMV seroprevalence, high-income populations indicate that vaccinating infants could be a highly efficient strategy to prevent cCMVi, even with only a modestly effective vaccine (i.e., <50% protective against primary infection). However, whether vaccinating infants is optimal in high CMV seroprevalence settings, where rates of cCMVi are correspondingly higher, is unclear. METHODS: We adjusted our existing agent-based stochastic model to study CMV vaccine efficacy in high seroprevalence settings (reaching 90%) with Brazil as a test case. RESULTS: Our results suggest that vaccinating 12-year-old girls and women of childbearing age would have limited ability to reduce cCMVi rates in Brazil, even with a vaccine conferring complete life-long protection against CMV infection. In contrast, vaccinating infants was predicted to provide substantial long-term reductions in the number of cCMVi cases in Brazil, even if it only induced protection equivalent to natural immunity against CMV reinfection and reactivation. Further, our model predicted that if two-thirds of Brazilian infants were vaccinated, a modestly effective vaccine would reduce the number of cCMVi cases by up to 76%. CONCLUSION: Together with results from other studies, this analysis underscores that infancy is likely the optimal target age for CMV vaccination to prevent cCMVi in all populations, regardless of the CMV seroprevalence. Furthermore, our findings predict large reductions in disease due to cCMVi worldwide through attainable vaccination scenarios.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gazeau S, Byrne C, Coombs D, et al. Mathematical modelling highlights the crucial role of early childhood immunization in preventing congenital CMV in countries with high CMV seroprevalence. Vaccine. 2026. PMID: 42269282. doi:10.1016/j.vaccine.2026.128788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。